See that on the site? If the primary objectives targets are achieved, Merck can approach FDA for fast track to market. Especially as I said, if their outcomes is better in terms of efficacy, toxicity and tolerability than what is out there. FDA has been know to fast track such outcomes for many other trials.
Column 1 Column 2 1 Estimated Primary Completion Date : July 31, 2023
The above is one of the main reason why IMU have stated many times that they won't be taking any drug candidate to a PH3 trial.
Why IMU is a multi multi bagger, page-8868
-
- There are more pages in this discussion • 16,223 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |